Wyeth Names 20-Year Veteran As New CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-time Wyeth exec Bernard Poussot will replace Robert Essner effective Jan. 1.
You may also be interested in...
Pending Drug Applications To Be Poussot’s Top Priority As Wyeth’s New CEO
Firm announces third quarter pharmaceutical earnings of $4.7 billion, up 10 percent year-over-year.
Pending Drug Applications To Be Poussot’s Top Priority As Wyeth’s New CEO
Firm announces third quarter pharmaceutical earnings of $4.7 billion, up 10 percent year-over-year.
Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear
FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.